Related Experiment Videos
Antibody-targeted therapy for low-grade lymphoma
1Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3332, USA.
Seminars in Hematology
|October 26, 1999
Summary
Monoclonal antibodies (MoAbs) targeting CD20, CD19, and CD22 offer effective non-Hodgkin's lymphoma (NHL) treatment. Radioimmunotherapy, using radioconjugates like 131I or 90Y, enhances tumor cell killing through a "cross-fire" effect.
Area of Science:
- Oncology
- Immunology
- Radiochemistry
Background:
- Monoclonal antibodies (MoAbs) are established treatments for B-cell non-Hodgkin's lymphoma (NHL).
- Common targets include CD20, CD19, and CD22.
- Unconjugated MoAbs induce tumor cell death via complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and apoptosis.
Purpose of the Study:
- To review the development and application of MoAbs in NHL treatment.
- To explore strategies for augmenting MoAb efficacy, including radioconjugates and immunotoxins.
- To highlight the potential of radioimmunotherapy in achieving tumor sterilization.
Main Methods:
- Review of clinical trials involving unconjugated MoAbs, immunotoxins (e.g., B4-blocked ricin), and radioimmunoconjugates (e.g., 131I, 90Y).
- Analysis of cytotoxic mechanisms of MoAbs.
- Evaluation of the
- cross-fire
- effect in radioimmunotherapy.
Main Results:
- MoAbs targeting CD20, CD19, and CD22 demonstrate efficacy in NHL.
- Radioconjugation of MoAbs with isotopes like 131I and 90Y is a promising strategy.
- Radioimmunotherapy offers a potential
- cross-fire
- effect to eliminate antigen-negative tumor cells.
Conclusions:
- MoAb-based therapies, particularly radioimmunotherapy, show significant potential for NHL treatment.
- Future research will focus on larger trials, combination therapies, and integration with chemotherapy and stem-cell transplantation.